Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years.
10.1016/j.apsb.2022.01.002
- Author:
Zhiran JU
1
;
Menglan LI
1
;
Junde XU
1
;
Daniel C HOWELL
1
;
Zhiyun LI
1
;
Fen-Er CHEN
1
Author Information
1. Institute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China.
- Publication Type:Review
- Keywords:
Adverse effects;
COX-2 inhibitors;
Cyclooxygenase;
Inflammation;
Prostaglandins
- From:
Acta Pharmaceutica Sinica B
2022;12(6):2790-2807
- CountryChina
- Language:English
-
Abstract:
Cyclooxygenases play a vital role in inflammation and are responsible for the production of prostaglandins. Two cyclooxygenases are described, the constitutive cyclooxygenase-1 and the inducible cyclooxygenase-2, for which the target inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins are a class of lipid compounds that mediate acute and chronic inflammation. NSAIDs are the most frequent choices for treatment of inflammation. Nevertheless, currently used anti-inflammatory drugs have become associated with a variety of adverse effects which lead to diminished output even market withdrawal. Recently, more studies have been carried out on searching novel selective COX-2 inhibitors with safety profiles. In this review, we highlight the various structural classes of organic and natural scaffolds with efficient COX-2 inhibitory activity reported during 2011-2021. It will be valuable for pharmaceutical scientists to read up on the current chemicals to pave the way for subsequent research.
